Nintedanib
( DrugBank: Nintedanib / KEGG DRUG: Nintedanib esylate, Nintedanib )
7 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 51 | Scleroderma | 36 |
| 84 | Sarcoidosis | 1 |
| 85 | Idiopathic interstitial pneumonia | 79 |
| 89 | Lymphangioleiomyomatosis | 2 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 227 | Osler disease | 3 |
| 228 | Bronchiolitis obliterans | 3 |
| 331 | Idiopathic multicentric castleman disease | 1 |
51. Scleroderma
Clinical trials : 639 / Drugs : 551 - (DrugBank : 157) / Drug target genes : 135 - Drug target pathways : 222
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
84. Sarcoidosis
Clinical trials : 175 / Drugs : 189 - (DrugBank : 80) / Drug target genes : 74 - Drug target pathways : 177
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
85. Idiopathic interstitial pneumonia
Clinical trials : 723 / Drugs : 411 - (DrugBank : 126) / Drug target genes : 104 - Drug target pathways : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
89. Lymphangioleiomyomatosis
Clinical trials : 44 / Drugs : 44 - (DrugBank : 20) / Drug target genes : 27 - Drug target pathways : 138
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
227. Osler disease
Clinical trials : 57 / Drugs : 60 - (DrugBank : 20) / Drug target genes : 25 - Drug target pathways : 151
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
228. Bronchiolitis obliterans
Clinical trials : 108 / Drugs : 95 - (DrugBank : 30) / Drug target genes : 34 - Drug target pathways : 158
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
331. Idiopathic multicentric castleman disease
Clinical trials : 40 / Drugs : 45 - (DrugBank : 29) / Drug target genes : 43 - Drug target pathways : 163
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|